Amgen, Inc.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1980-01-01
- Employees
- 26.7K
- Market Cap
- $175.6B
- Website
- http://www.amgen.com
Study to Investigate the Effect of Rocatinlimab (AMG 451) on the Pharmacokinetics of Multiple Cytochrome P450 (CYP450) Substrates in Participants With Moderate to Severe Atopic Dermatitis
- Conditions
- Atopic Dermatitis
- Interventions
- Dietary Supplement: CaffeineDietary Supplement: Vitamin K
- First Posted Date
- 2023-06-06
- Last Posted Date
- 2025-01-20
- Lead Sponsor
- Amgen
- Target Recruit Count
- 21
- Registration Number
- NCT05891119
- Locations
- 🇺🇸
Direct Helpers Research Center (DHRC), Hialeah, Florida, United States
🇺🇸Velocity Clinical Research -Spartanburg, Spartanburg, South Carolina, United States
🇺🇸DermDox Dermatology Centers, PC - Sugarloaf, Nashville, Tennessee, United States
A Study to Evaluate the Pharmacokinetics, Safety and Tolerability of AMG 592 in Healthy Japanese Participants
- Conditions
- Chronic Graft-versus-Host Disease (cGVHD)
- Interventions
- Other: Placebo
- First Posted Date
- 2023-06-02
- Last Posted Date
- 2023-06-02
- Lead Sponsor
- Amgen
- Target Recruit Count
- 18
- Registration Number
- NCT05885451
- Locations
- 🇦🇺
Research Site, Randwick, New South Wales, Australia
A Study to Assess Long-term Safety, Tolerability, and Efficacy of Rocatinlimab in Adult and Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
- First Posted Date
- 2023-05-31
- Last Posted Date
- 2025-05-22
- Lead Sponsor
- Amgen
- Target Recruit Count
- 2200
- Registration Number
- NCT05882877
- Locations
- 🇭🇺
Medmare Bt, Veszprem, Hungary
🇱🇻Outpatient clinic Veselibascentrs 4, Riga, Latvia
🇵🇱Twoja przychodnia Pcm, Poznan, Poland
A Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Pharmacodynamics of AMG 592 in Healthy Participants
- Conditions
- Chronic Graft-versus-host Disease (cGVHD)
- Interventions
- Other: Placebo
- First Posted Date
- 2023-05-24
- Last Posted Date
- 2023-05-24
- Lead Sponsor
- Amgen
- Target Recruit Count
- 64
- Registration Number
- NCT05873907
- Locations
- 🇺🇸
Research Site, Aventura, Florida, United States
Study to Explore the Safety, Tolerability, and Pharmacokinetics of AMG 305 in Subjects With Advanced Solid Tumors
- First Posted Date
- 2023-04-06
- Last Posted Date
- 2025-05-08
- Lead Sponsor
- Amgen
- Target Recruit Count
- 220
- Registration Number
- NCT05800964
- Locations
- 🇩🇪
Universitaetsklinikum Essen, Essen, Germany
🇬🇧Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom
🇺🇸City of Hope National Medical Center, Duarte, California, United States
A Study of Apremilast in Children With Oral Ulcers Associated With Behçet's Disease or Juvenile Psoriatic Arthritis
- Conditions
- Behçet's DiseaseJuvenile Psoriatic Arthritis
- Interventions
- First Posted Date
- 2023-03-14
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 48
- Registration Number
- NCT05767047
- Locations
- 🇹🇷
Hacettepe Universitesi Tip Fakultesi Hastanesi, Ankara, Turkey
🇬🇷General Hospital of Thessaloniki Ippokrateio, Thessaloniki, Greece
🇮🇱Meir Medical Center, Kfar Saba, Israel
Study Comparing Tarlatamab With Standard of Care Chemotherapy in Relapsed Small Cell Lung Cancer
- Conditions
- Small Cell Lung Cancer (SCLC)
- Interventions
- First Posted Date
- 2023-02-23
- Last Posted Date
- 2025-05-18
- Lead Sponsor
- Amgen
- Target Recruit Count
- 509
- Registration Number
- NCT05740566
- Locations
- 🇧🇪
Vitaz campus Sint-Niklaas Moerland, Sint-Niklaas, Belgium
🇧🇷Beneficencia Portuguesa de Sao Paulo - Bp, Sao Paulo, São Paulo, Brazil
🇦🇺Liverpool Hospital, Liverpool, New South Wales, Australia
A Study Assessing Rocatinlimab in Combination With Topical Corticosteroid and/or Topical Calcineurin Inhibitors in Adult Participants With Moderate-to-severe Atopic Dermatitis (AD)
- First Posted Date
- 2023-02-13
- Last Posted Date
- 2025-02-07
- Lead Sponsor
- Amgen
- Target Recruit Count
- 746
- Registration Number
- NCT05724199
- Locations
- 🇭🇺
Csalogany Orvosi Kozpont, Budapest, Hungary
🇭🇺Clinexpert Kft, Budapest, Hungary
🇭🇺Obudai Egeszsegugyi Centrum Kft, Zalaegerszeg, Hungary
A Study to Evaluate Rocatinlimab (AMG 451) in Adolescent Participants With Moderate-to-severe Atopic Dermatitis (AD)
- Conditions
- Atopic Dermatitis
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-01-30
- Last Posted Date
- 2024-12-11
- Lead Sponsor
- Amgen
- Target Recruit Count
- 500
- Registration Number
- NCT05704738
- Locations
- 🇯🇵
Suizenji Dermatology Clinic, Kumamoto-shi, Kumamoto, Japan
🇯🇵Yoshioka Dermatology Clinic, Neyagawa-shi, Osaka, Japan
🇯🇵Dermatology and Ophthalmology Kume Clinic, Sakai-shi, Osaka, Japan
A Study to Evaluate ABP 938 and Aflibercept (Eylea®) in Participants With Chorioretinal Vascular Disease (CVD)
- First Posted Date
- 2023-01-30
- Last Posted Date
- 2025-02-14
- Lead Sponsor
- Amgen
- Target Recruit Count
- 49
- Registration Number
- NCT05704725
- Locations
- 🇺🇸
Retina Consultants of Texas - Bellaire Retina Center, Bellaire, Texas, United States
🇺🇸Retinal Consultants of Texas - San Antonio Retina Center, San Antonio, Texas, United States
🇺🇸Retina Consultants of Texas - Austin Retina, Austin, Texas, United States